Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
07/2003
07/02/2003EP1322651A1 Bicyclic heteroaromatic compounds
07/02/2003EP1322631A2 Methods of providing and using compounds ( retinoids ) having activity as inhibitors of cytochrome p450rai
07/02/2003EP1322628A2 Substituted urea neuropeptide y y5 receptor antagonists
07/02/2003EP1322598A1 Nitroso diphenylamine derivatives
07/02/2003EP1322350A1 E-ptfe foil impregnated with an encapsulated bioactive substance
07/02/2003EP1322338A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses
07/02/2003EP1322336A1 Method of increasing testosterone and related steroid concentrations in women
07/02/2003EP1322333A2 Composition for combined use of aromatase inhibitors
07/02/2003EP1322300A1 Inhalation particles incorporating a combination of two or more active ingredients
07/02/2003EP1322286A2 Polymeric delivery formulations of leuprolide with improved efficacy
07/02/2003EP1218372B1 Novel heterocyclic compounds useful as reversible inhibitors of cysteine proteases
07/02/2003EP1171444B1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
07/02/2003EP0879282B1 Immunotherapy using cytotoxic t lymphocytes (ctl)
07/02/2003EP0732875B1 Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
07/02/2003CN1427825A Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
07/02/2003CN1427730A Medicinal aerosol formulation
07/02/2003CN1426812A Relaxation of Climacteric syndrome by using antisenility action of glossy ganoderma
07/01/2003US6586456 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide
07/01/2003US6586436 Serotonergic agents
07/01/2003US6586402 Leucine replaced by neopentylglycine or adamantylalanine
07/01/2003US6585997 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
07/01/2003US6585970 Method for treating hypothyroidism
06/2003
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051903A1 Androstane derivative having substituent in 7- and 17-positions
06/26/2003WO2003051888A1 6-aminomorphinane derivatives, method for the production and use thereof
06/26/2003WO2003051885A1 Nitrogen-containing heterocyclic compounds and use thereof
06/26/2003WO2003051872A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists
06/26/2003WO2003051863A1 SUBSTITUTED 6H-DIBENZO[c,h]CHROMENES AS ESTROGENIC AGENTS
06/26/2003WO2003051860A2 Substituted 2-phenyl benzofurans as estrogenic agents
06/26/2003WO2003051842A2 Compositions decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051805A2 Substituted phenyl naphthalenes as estrogenic agents
06/26/2003WO2003051372A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003WO2003051371A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/26/2003WO2003051365A2 Use of compounds of the benzamide family as immunosuppressant
06/26/2003WO2003051337A1 Pre-formulation for the tabletting of natural mixtures of conjugated estrogens
06/26/2003WO2003051336A1 Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051328A1 Solid dose micro implant
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2002087606A3 Modulators of the hypocretin system and methods of screening therefor
06/26/2003US20030120224 Feminine care products for the delivery of therapeutic substances
06/26/2003US20030120081 Process for the preparation of non-steroidal glucocorticoid receptor modulators
06/26/2003US20030119911 Levothyroxine sodium and liothyronine sodium in solid form with microcrystalline cellulose; treating hypothyroidism and thyroid hormone replacement therapy
06/26/2003US20030119878 A 1-arylalkyl-3-aminoalkyl-1,4-dihydropyrid-4-one derivative; sexual disorders; anticarcinogenic agents; benign prostatic hypertrophy/fibroids of the uterus; endometriosis, polycystic ovarian disease, precocious puberty; contraceptives
06/26/2003US20030119841 Treatment and prevention of anxiety and convulsive disorders
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119801 Stabilized tibolone compositions
06/26/2003US20030119800 Administering an ANGELS (Activators of Non-Genotropic Estrogen-like Signaling compound"ANGELS") compound to maintain or increase bone mass, bone density and/or bone strength.
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119728 Stable, nasally, orally or sublingually applicable pharmaceutical preparation
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030118990 Novel estrogen-regulated G protein gamma subunit: compositions and methods of use
06/26/2003US20030118638 Oral pharmaceutical products containing 17 beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
06/26/2003US20030118610 Oral delivery of peptides using enzyme-cleavable membrane translocators
06/26/2003CA2470352A1 Substituted 2-phenyl benzofurans as estrogenic agents
06/26/2003CA2470209A1 Pre-formulation for the tabletting of natural mixtures of conjugated estrogens
06/26/2003CA2469950A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2446292A1 Nucleic acid-associated proteins
06/25/2003EP1321149A1 Compositions for relieving symptoms of menopausal syndrome
06/25/2003EP1321146A2 Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
06/25/2003EP1321141A1 Parathyroid hormone production inhibitors containing vitamin d3 derivatives
06/25/2003EP1320710A1 Drying method for selectively removing volatile components from wet coatings
06/25/2003EP1320600A1 Transporters and ion channels
06/25/2003EP1320548A2 Transporters and ion channels
06/25/2003EP1320541A2 Tgf-beta inhibitors and methods
06/25/2003EP1320387A2 Pharmaceutical compositions for sustained drug delivery
06/25/2003EP1320359A2 Thermogelling biodegradable aqueous polymer solution
06/25/2003EP1140110B1 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions
06/25/2003EP1025125B1 Aggregates of human insulin derivatives
06/25/2003EP1000008B1 Novel thyroid receptor ligands and method
06/25/2003EP0877807B1 Biologically active and particularly peptide molecules having a potentiating effect on growth hormone biological activity
06/25/2003CN1426412A Novel compounds
06/25/2003CN1426409A Inhibitors of dipeptidyl peptidase IV
06/25/2003CN1426395A Inhibitors of dipeptidyl peptidase IV
06/25/2003CN1426394A Novel compounds
06/25/2003CN1426393A Novel compounds
06/24/2003US6583309 Ureas and compositions thereof for treating cancer, inflammation, or a viral infection
06/24/2003US6583179 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
06/24/2003US6583145 Thio-oxindole derivatives
06/24/2003US6583143 CRF receptor antagonists and methods relating thereto
06/24/2003US6583129 Administration of non-oral androgenic steroids to women
06/24/2003US6582728 On carrier of human serum albumin, carbohydrate, amino acid, polypeptide, buffer and/or salts; drug delivery to lungs
06/19/2003WO2003050108A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003WO2003050095A1 Substituted benzoxazoles and analogues as estrogenic agents
06/19/2003WO2003050067A2 Vitamin d analogues
06/19/2003WO2003049774A1 Transdermal transport of compounds
06/19/2003WO2003049717A2 Conductance of improperly folded proteins through the secretory pathway and related treatments of diseases
06/19/2003WO2003049673A2 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003WO2003005960A3 Novel bicyclic and tricyclic cannabinoids
06/19/2003WO2001008635A3 Calcium channel transport polynucleotides, polypeptides, and antibodies
06/19/2003US20030114683 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
06/19/2003US20030114524 An antiestrogenic agent containining aromatic or heteroaromatic compounds containing hydroxycarbonyl or metal salt- halogenoalkyl side chain; useful for treating breast cancer
06/19/2003US20030114521 Oxamic acids and derivatives as thyroid receptor ligands
06/19/2003US20030114513 Use of isatin derivatives as ion channel activating agents
06/19/2003US20030114456 Antiinflammatory agents, analgesics, antipyretics
06/19/2003US20030114455 Sexual disorders
06/19/2003US20030114440 Compositions and methods of treatment for conditions responsive to testosterone elevation
1 ... 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 ... 290